Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF | V.TLT.W

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Bullboard Posts
Comment by Claridgeon May 22, 2019 6:17pm
81 Views
Post# 29766233

RE:RE:RE:RE:RE:RE:RE:Presentation to the 74th Annual Meeting of the CUA

RE:RE:RE:RE:RE:RE:RE:Presentation to the 74th Annual Meeting of the CUAA bit of the structures (Excellence centers, etc ...) that HempDoc refered to.  There are networks that exist to bring faster new treatments to bedside, for the benefit of the patients.


Taken from the PMH website:



World-Leading Clinical Trials Program

Our Phase I clinical trials program is the largest in Canada and one of the top-rated programs of its kind worldwide. It is the only Phase I program in Canada to receive a grant from the U.S. National Cancer Institute (NCI).

We have leveraged our clinical trials expertise to form and lead The Princess Margaret Phase II Consortium, which is a network of 12 cancer centres across Canada and the U.S. This is the only site outside of the U.S. to secure a contract with the U.S. NCI.

Recognized Global Centre of Excellence

We are proud that Princess Margaret Cancer Centre is the only Canadian cancer institution among six global cancer centres selected by GlaxoSmithKline as a preferred centre of excellence to expedite translation of scientific knowledge into laboratory research and clinical trials.

Leaders in Participation for Clinical Trials

Our clinical trials program is the largest in Canada and one of the largest in the world, with over 700 active trials, and 1 in 6 new patients enrolled onto a clinical trial.

Our cancer centre is the only non-U.S.  site chosen to be part of the Cancer Immunotherapy Trials Network funded by the U.S. NCI.
 

Bullboard Posts